Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice TargetHot
Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $44 to $56.
Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $44 to $56.